1. Antiasthmatics This study material is recommended specifically for practical courses from Pharmacology II for students of general medicine and stomatology. These brief notes could be used to prepare for the lesson and as a base for own notes during courses. Addititonal explanations and information are given in single lessons.

2. Asthma bronchiale = chronic respiratory tract inflammation prevalence in CZ: children 10-15 %, adults 3-5 %

3. Asthma bronchiale Constriction of bronchial smooth muscles Edematous changes on bronchial mucosa Increased mucus production and secretion Symptoms breathlessness - breathlessness caused by bronchoconstriction, oedema, bronchial inflammation and mucus difficult expiration, - difficult expiration, prolonged expiration, whistling, creaking. - cough

4. Patophysiology Genetic predisposition Immune response deviation Early contact with allergens environmental factors diet, mother‘s health Early sensibilisation Inducers (allergens, viruses, irritants) INFLAMMATION airways remodelation Bronchial hyperreactivity Symptoms triggers

5. Diagnose Anamnesis – personal, familiar Clinical examinations - auscultation, signs of atopy, eosinophylia, PEF – Peak Expiratory Flow FEV – Forced Expired Volume Laboratory tests- eosinophilia, IgE, Allergy testing

6. Astham bronchiale classification allergicnon-allergic inducerconatct with allergen infection psychogennic phys. activity irritation aspirin ↑ of probabilityyoung patients older patients

7. Classification with regard to seriousness Intermitent – sign up to once a week, night symptoms up to twice a month, pulmonary function normal Intermitent – sign up to once a week, night symptoms up to twice a month, pulmonary function normal Mild persistent– signs no more than once daily, Mild persistent– signs no more than once daily, night symptoms up to twice a month, PEF at least 80 % night symptoms up to twice a month, PEF at least 80 % Moderate persistent– signs once a day and are not permanent, night sign no more than once a week, PEF 60-80 % Moderate persistent– signs once a day and are not permanent, night sign no more than once a week, PEF 60-80 % Severe persistent– permanent signs, daily, obstruction, PEF ≤ 60 % Severe persistent– permanent signs, daily, obstruction, PEF ≤ 60 %

8. Administration of antiasthamtics Peroral Peroral Injections Injections Inhalation Inhalation benefits: high drug concentration on the site of action fast onset of effect minimal penetration to systemic circulation = low risk of systemic AE

9. Inhalation preparation for antiasthmatics Aerosol dispensers – meter dose dispensers Aerosol dispensers – meter dose dispensers Aerosol dispenser + spacer – children elders Aerosol dispenser + spacer – children elders Powder (spinhaler, dischaler, turbohaler) Powder (spinhaler, dischaler, turbohaler) Nebulizer Nebulizer

10. Asthma bronchiale pharmacotherapy Quick relief drugs – acute attack Quick relief drugs – acute attack Long-term control medicines – between attacks Long-term control medicines – between attacks

11. Pharmacotherapy 1. Bronchodilators β-sympathomimetics β-sympathomimetics nonselective sympothomimetics nonselective sympothomimetics antimuscarinics antimuscarinics methylxanthines methylxanthines 2. Antiinflammatory agents Glucocorticoids Glucocorticoids Immunoprophylactics Immunoprophylactics 3. Adjuvant therapy and other drugs of respiratory system Antileucotriens Antileucotriens leucotriens‘ receptors antagonists. leucotriens‘ receptors antagonists. 5-LOX inhibitors 5-LOX inhibitors Antighistamines Antighistamines Expectorants Expectorants Antitussives Antitussives Hyposensibilisation Hyposensibilisation Anti IgE monoclonal antibodies Anti IgE monoclonal antibodies

12. 1. Bronchodilators β- sympathomimetics selective stimulation of β 2 -Rc selective stimulation of β 2 -Rc adenylate cyclase stimulation → ↑cAMP → bronchial smooth muscles relaxation adenylate cyclase stimulation → ↑cAMP → bronchial smooth muscles relaxation decrease of inflammation mediators from mastocytes decrease of inflammation mediators from mastocytes increase cilliar activity increase cilliar activity

13. Short-acting (max. 4 - 6 hrs.) Short-acting (max. 4 - 6 hrs.)salbutamol fenoterol terbutaline hexoprenaline 1. Bronchodilators β- sympathomimetics

14. Long- acting (12 hrs.) Long- acting (12 hrs.)prokaterolformoterolsalmeterolclenbuterolbambuterol 1. Bronchodilators β- sympathomimetics

15. AE: AE: nervosity, tremor, cephalgia, palpitation hypokalemia CI: CI: dysrhythmia, hypertension (pregnancy) 1. Bronchodilators β- sympathomimetics

16. 1.Bronchodilators Nonselective sympathomimetics epinephrine– in life-threatening situations ephedrine orciprenaline More of AE tachycardia, palpitation, dysrhythmia, hyper/hypo tension, insomnia

17. 1. Bronchodilators Antimuscarinics for inhalation for inhalation blocks cholinergic M receptors blocks cholinergic M receptors to increase the effect of β 2 -sympathomimetics to increase the effect of β 2 -sympathomimeticsipratropiumtiotropium atropine analogues, inhalation in combination with beta- mimetics – or administration after beta-mimetics when combined sith corticoids, then administered after them AE: drymouth, urine retention, constipation AE: drymouth, urine retention, constipation CI: prostate hypertrophy, glaucoma, pregnancy CI: prostate hypertrophy, glaucoma, pregnancy

18. 1. Bronchodilators Methylxanthines phosphodiesterase inhibitors → ↓ cAMP degradation → smooth muscle relaxation bronchodilators, cardiostimulants, diuretics retarded DDF (before going to bed) theophylline aminophylline ethophylline

19. adenosine receptor antagonists (adenosine  contraction,  His, LT, Pg) More effects: CNS stimulation; +chrono, +inotropic effect  blood viscosity and hemoperfusion (pentoxiphillin) gastric acid secretion increase AE: similar to those of nonselective sympathomimetics 1. Bronchodilators Methylxanthines

20. Bronchodilators target sites on smooth muscle cells mastocyte HistamineH 1 receptor vagus ACH cholinergic rcp. α - receptor cAMP β 2 adrenergics β 2 rcp. PDE inhibitors (methylxanthines) α blockade Antimuscarinics cromolyn, ketotifen H 1 Antihistamines

21. Pharmacotherapy 1. Bronchodilators β-sympathomimetics β-sympathomimetics nonselective sympothomimetics nonselective sympothomimetics antimuscarinics antimuscarinics methylxanthines methylxanthines 2. Antiinflammatory agents Glucocorticoids Glucocorticoids Immunoprophylactics Immunoprophylactics 3. Adjuvant therapy and other drugs of respiratory system Antileucotriens Antileucotriens leucotriens‘ receptors antagonists. leucotriens‘ receptors antagonists. 5-LOX inhibitors 5-LOX inhibitors Antighistamines Antighistamines Expectorants Expectorants Antitussives Antitussives Hyposensibilisation Hyposensibilisation Anti IgE monoclonal antibodies Anti IgE monoclonal antibodies

22. 2. Antiinflammatory agents Glucocorticoids antiinflammatory and immunosuppressant activity (PLA 2 inhibition) ↓ cytokines, prostaglandines and leucotriens secretion ↓ cytokines, prostaglandines and leucotriens secretion ↓ lipolytic and proteolytic enzymes secretion ↓ lipolytic and proteolytic enzymes secretion ↓ endothelial permeability ↓ endothelial permeability

23. block cell migration and decrease bronchial hypereactivity, suppress oedema block chronic ireversible changes development (bronchial smooth muscles hypertrofia and hyperplasia, subendothelial fibrosis and thickening of mucous basal membrane) - increase sensivity of  adrenergic receptors to beta mimetics 2. Antiinflammatory agents Glucocorticoids

24. Orally or inhalation Inhalation Inhalationbeclomethasonebudesonide fluticasoneflunisolidedexamethasone AE: hoarseness, cough, oral candidosis (wash out mouth after use) 2. Antiinflammatory agents Glucocorticoids

25. Orally Orally when inhalation are not sufficient in challenge doses which are gradually decreased prednisonetriamcinolonebetamethasone 2. Antiinflammatory agents Glucocorticoids

26. AE: candidosis, risk of systemic adverse effects(+ in combinations with LABA) systemic: Cushing‘s sy., DM, immunosuppresion, ostoporosis, hypertension, gastroduodenal ulcers... 2. Antiinflammatory agents Glucocorticoids

27. mast cells membrane stabilizers mast cells membrane stabilizers inhibit histamine release inhibit histamine release influence on lymphocytes influence on lymphocytes in mild forms of asthma prevention of asthma attacks, maintainance therapy cromoglycatenedocromil ketotifen (H1 antagonist, anti-Ach effect) CI: 1. trimester of pregnancy 2. Antiinflammatory agents Immunoprophylactics

28. Pharmacotherapy 1. Bronchodilators β-sympathomimetics β-sympathomimetics nonselective sympothomimetics nonselective sympothomimetics antimuscarinics antimuscarinics methylxanthines methylxanthines 2. Antiinflammatory agents Glucocorticoids Glucocorticoids Immunoprophylactics Immunoprophylactics 3. Adjuvant therapy and other drugs of respiratory system Antileucotriens Antileucotriens leucotriens‘ receptors antagonists. leucotriens‘ receptors antagonists. 5-LOX inhibitors 5-LOX inhibitors Antighistamines Antighistamines Expectorants Expectorants Antitussives Antitussives Hyposensibilisation Hyposensibilisation Anti IgE monoclonal antibodies Anti IgE monoclonal antibodies

29. 3. Adjuvant therapy Antileucotriens for mild forms of asthma in serious asthma in combination with gorticoids a) Leucotrien receptor antagonists montelukastzafirlukast b) 5-lipoxigenase inhibitors(5-LOXi) zileutonpiriprostdocebenone c) Both effects (antag. rcp. + i 5-LOX) tenidap

30. 3. Adjuvant therapy Antihistamines 2nd generation antihistamines with minimal sedative and arrhythmogenic effects desloratadinelevocetirizinefexofenadineketotifen

31. Secretolytics Secretolytics bronchila gland stimulation = liquid mucus ammonium chloride potassium iodide saponines – Primula, Verbascum 3. Adjuvant therapy Expectorants

32. Mucolytics- decrease of mucus viscosity Mucolytics- decrease of mucus viscosityN-acetylcysteinecarbocysteineambroxol bromhexine (pro-drug) erdosteine 3. Adjuvant therapy Expectorants

33. Secretomotorics Secretomotorics increase cilliar activity essential oils: oleum eucalypti, o. menthae piperitae bromhexine (pro-drug) ambroxolOthersguaifenesineemetine 3. Adjuvant therapy Expectorants

34. Cough = reflexive activity produced to release or clean up airways symptomatic therapy of irritating and exhausting cough symptomatic therapy of irritating and exhausting cough do not combine with expectorants, namely secretomotorics for antagonistic effects do not combine with expectorants, namely secretomotorics for antagonistic effects 3. Adjuvant therapy Antitussives

35. Block of cough center Block of cough centercodeinpholcodineethylmorphinedextrometorphanlevopropoxyphen AE: respiratory center suppression → not for children! 3. Adjuvant therapy Codiene antitussives

36. Block of sensitive neurons in submucosa Block of sensitive neurons in submucosadropropizinebezonatate Block of afferent pathways Block of afferent pathwaysprenoxdiazine 3. Adjuvant therapy Non-codeine antitussives - peripheral

37. Block of cough cetre, but do not suppress respiratory center Block of cough cetre, but do not suppress respiratory centerbutamirate (clobutinol – withdrawn!!!) Block of efferent pathways Block of efferent pathwaysmyorelaxanciaganglioplegika I: surgery 3. Adjuvant therapy Non-codeine antitussives - central